RT Journal Article
T1 Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
A1 Oliver-Martos, Begoña
A1 Fernández, Óscar
A1 Orpez, Teresa
A1 Alvarenga, Marco Papais
A1 Pinto-Medel, María Jesús
A1 Guerrero, Miguel
A1 León, Antonio
A1 López-Madrona, José Carlos
A1 Maldonado-Sánchez, Rafael
A1 García-León, Juan Antonio
A1 Luque, Gloria
A1 Fernández, Victoria
A1 Leyva-Fernández, Laura
K1 Esclerosis múltiple
AB Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that may affect the efficacy and safety of the drug. In this observational study, the kinetics of the appearance and the incidence of anti-natalizumab antibodies were followed prospectively for 18 months in a cohort of 64 consecutive patients treated with natalizumab for relapsing MS. Blood samples were drawn immediately before starting natalizumab therapy and each month afterwards. The presence of antibodies against natalizumab was assessed by enzyme-linked immunosorbent assay (ELISA) in all patients. Anti-natalizumab antibodies were detected in nine (14.1%) natalizumab-treated patients, three (4.68%) of whom were transiently positive while six (9.37%) were persistently positive (these patients discontinued natalizumab). All positive titres were observed during the first 4 months of treatment. One patient with a hypersensitivity reaction also had persistent antibodies. We conclude that antibodies against natalizumab develop early, within the first 6 months of therapy with natalizumab. Although no antibodies were detected after 4 months of therapy in this particular study, this does not rule out their development later on in exceptional cases.
PB SAGE
YR 2011
FD 2011-03
LK https://hdl.handle.net/10630/34502
UL https://hdl.handle.net/10630/34502
LA eng
NO Begoña Oliver, Oscar Fernández, Teresa Orpez, Marcos Papais Alvarenga, María Jesús Pinto-Medel, Miguel Guerrero, Antonio León, José Carlos López-Madrona, Rafael Maldonado-Sánchez, Juan Antonio García-León, Gloria Luque, Victoria Fernández, Laura Leyva. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler. 2011 Mar;17(3):368-71.  doi: 10.1177/1352458510385508.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026